• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $HLTH

    Cue Health Inc.

    Subscribe to $HLTH
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    IPO Year: 2021

    Exchange: NASDAQ

    Recent Analyst Ratings for Cue Health Inc.

    DatePrice TargetRatingAnalyst
    3/14/2024Buy → Neutral
    BTIG Research
    10/19/2021$18.00Buy
    BTIG Research
    10/19/2021$12.00Equal-Weight
    Morgan Stanley
    10/19/2021$19.00Buy
    Goldman Sachs
    10/19/2021$14.00Outperform
    Cowen & Co.
    See more ratings

    Cue Health Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cue Health to Pursue Wind Down of the Business

      Cue Health Inc. ("Cue" or the "Company") (NASDAQ:HLTH), a healthcare technology company, today announced the Company has filed voluntary petitions under Chapter 7 of the U.S. Bankruptcy Code in the District of Delaware to pursue a wind down of its business. Cue has been working diligently to strengthen the Company's financial foundation, including taking a number of actions to reduce costs and improve operational efficiency. Cue also undertook an extensive process to locate additional financing or effect a strategic transaction. Despite its best efforts and after a comprehensive review, Cue's Board of Directors in consultation with the Company's advisors, has concluded that it is in the b

      5/28/24 4:31:00 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cue Health Evaluating Warning Letter Received from Food and Drug Administration (FDA)

      Cue Health Inc. (NASDAQ:HLTH), a healthcare technology company (the "Company"), has received a warning letter from the FDA about its Emergency Use Authorized (EUA) COVID-19 test. The Company is currently evaluating the letter and determining its response, with more information to follow in the next few days. About Cue Cue Health Inc. (NASDAQ:HLTH) is a healthcare technology company that empowers healthcare providers to streamline their ability to deliver value-based care with fast, highly accurate test results on demand. Cue received De Novo authorization from the U.S. Food and Drug Administration (FDA) for its COVID-19 test, which became the first home use respiratory test to receive t

      5/13/24 8:30:00 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cue Health to Announce First Quarter Financial Results

      Cue Health Inc. ("Cue") (NASDAQ:HLTH), a healthcare technology company, announced today that it will release its first quarter 2024 financial results on Monday, May 13, 2024. The company will not be hosting a conference call. About Cue Health Cue Health Inc. (NASDAQ:HLTH) is a healthcare technology company that uses diagnostic-enabled care to empower people to live their healthiest lives. Cue's platform offers individuals and healthcare providers convenient and personalized access to lab-quality diagnostic tests at home and at the point-of-care, as well as on-demand telehealth consultations and treatment options for a wide range of health and wellness needs. Cue's customers include fede

      4/29/24 4:01:00 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cue Health Announces Strategic Actions to Position Company for Next Stage

      Clint Sever Appointed CEO Board Appoints Two Strategic Advisors Who Bring Significant Industry Expertise Cue Health Inc. ("Cue" or the "Company") (NASDAQ:HLTH), a healthcare technology company, today announced strategic actions implemented by its Board of Directors (the "Board") to best position the Company for its next stage: Clint Sever, co-founder and current Chief Product Officer, has been appointed CEO, effective immediately. Sever succeeds Ayub Khattak, who is stepping down as Chief Executive Officer, President, and Chairman. Khattak will remain a member of the Board of Directors. The Board has appointed two strategic advisors, who have specific subject matter expertise in i

      3/20/24 5:21:00 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cue Health Reports Fourth Quarter 2023 Financial Results

      Cue Health Inc. ("Cue" or the "Company") (NASDAQ:HLTH), a healthcare technology company, today reported financial results for the fourth quarter and full-year 2023. Recent Highlights Reported fourth quarter total revenue of $18.8 million. Full-year 2023 total revenue was $70.9 million Submitted additional clinical samples and stability data for RSV to the FDA in support of de novo submission Submitted additional clinical samples and gathering additional stability data for Flu A/B to the FDA in support of de novo submission In late stage development of Herpes + Mpox Multiplex Molecular Test with plan to submit for EUA in 2Q24 Executed cost reduction plans, resulting in cash

      3/13/24 4:01:00 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cue Health to Announce Fourth Quarter and Full Year 2023 Financial Results

      Cue Health Inc. ("Cue") (NASDAQ:HLTH), a healthcare technology company, announced today that it will release its fourth quarter and full year 2023 financial results on Wednesday, March 13, 2024. In conjunction with the release, Cue will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. To access the live call via telephone, please register in advance using the link here. Upon registering, each participant will receive an email confirmation with dial-in numbers and a unique personal PIN that can be used to join the call. The live webinar of the call may be accessed by visiting the Events

      2/28/24 4:01:00 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cue Health Announces Appointment of Rishi Reddy to Board of Directors

      Cue Health (NASDAQ:HLTH), a healthcare technology company, today announced it entered into a cooperation agreement (the "Cooperation Agreement") with Tarsadia Investments ("Tarsadia"), and appointed Rishi Reddy to its board of directors (the "Board"), effective immediately. Mr. Reddy is a Managing Director at Tarsadia, where he leads the firm's venture and growth equity strategy. He was previously an Observer on Cue's Board of Directors from April 2018 to September 2021. In addition, the Board intends to commence a process to add an additional highly qualified, independent director to the Board. "Cue remains focused on creating value for all of its stakeholders," said Ayub Khattak, Chairm

      2/16/24 5:00:00 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cue Health to Participate at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

      Cue Health ("Cue") (NASDAQ:HLTH), a healthcare technology company, announced today that its management team will participate at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 13, 2024. About Cue Health Cue Health Inc. (NASDAQ:HLTH) is a healthcare technology company that uses diagnostic-enabled care to empower people to live their healthiest lives. The Cue Health platform offers individuals and healthcare providers convenient and personalized access to lab-quality diagnostic tests at home and at the point-of-care, as well as on-demand telehealth consultations and treatment options for a wide range of health and wellness needs. Cue's custo

      1/31/24 4:01:00 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cue Health Reports Third Quarter 2023 Financial Results

      Cue Health Inc. ("Cue") (NASDAQ:HLTH), a healthcare technology company, today reported financial results for the third quarter 2023. Recent Highlights Reported third quarter total revenue of $17.5 million, approximately 50% above the midpoint of our guidance range of $11 to $13 million. Three tests in review with the FDA: Cue® Flu A/B + COVID-19 Multiplex Molecular Test Emergency Use Authorization (EUA) for at-home and point-of-care use. Cue Flu A/B Molecular Tests De Novo application for at-home and point-of-care use. Cue RSV Molecular Test De Novo application for at-home and point-of-care use. Flu A/B, RSV, and COVID Multiplex Molecular Test development program is pr

      11/8/23 4:01:00 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Cue Health to Announce Third Quarter 2023 Financial Results

      Cue Health Inc. ("Cue") (NASDAQ:HLTH), a healthcare technology company, announced today that it will release its third quarter 2023 financial results on Wednesday, November 8, 2023. In conjunction with the release, Cue will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. To access the live call via telephone, please register in advance using the link here. Upon registering, each participant will receive an email confirmation with dial-in numbers and a unique personal PIN that can be used to join the call. The live webinar of the call may be accessed by visiting the Events section of th

      10/25/23 4:01:00 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    Cue Health Inc. FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • June 6, 2023 - FDA Permits Marketing of First COVID-19 At-Home Test Using Traditional Premarket Review Process

      For Immediate Release: June 06, 2023 Today, the U.S. Food and Drug Administration granted marketing authorization for the Cue COVID-19 Molecular Test. The product is a molecular nucleic acid amplification test (NAAT) that is intended to detect genetic material from SARS-CoV-2 virus present in nasal swabs from adults with signs and symptoms of upper respiratory infection. This test is the first at-home over-the-c

      6/6/23 3:04:14 PM ET
      $HLTH
      Biotechnology: Laboratory Analytical Instruments
      Industrials